New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Oncolytics Biotech's Advances: Oncolytics Biotech Inc. is gaining attention for its immunotherapy drug, pelareorep, which shows promise in converting "cold" pancreatic tumors into "hot" ones, enhancing their vulnerability to immune attacks. Upcoming data from the GOBLET study will be presented at the 2025 ASCO Annual Meeting, highlighting significant clinical trial results.
Market Growth and Collaborations: The cancer treatment market is projected to expand significantly, with immunotherapy expected to reach a $1.2 trillion market size by 2033. Other companies like Akoya Biosciences and TScan Therapeutics are also making strides, reporting revenue growth and advancing collaborations aimed at improving cancer diagnostics and therapies.
Analyst Views on TCRX
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.140
Low
3.00
Averages
5.50
High
7.00
Current: 1.140
Low
3.00
Averages
5.50
High
7.00
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
